Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pertuzumab

Roche Basel Switzerland

Roche invests $879m in its biologics future

Expects to create around 500 new jobs in Switzerland, Germany and the US

- PMLiVE

NICE backs Roche’s MabThera in rare autoimmune disease

Overturns previous negative draft guidance from England's cost-effectiveness body

healthcare data technology

Data technology and value-based pricing

The value of adding post-approval data collating, monitoring and analysis to any discussion on drug pricing systems

- PMLiVE

FDA gives green light to Roche for early Perjeta in breast cancer

Oncology drug can now be used before surgery in the US

- PMLiVE

UK breast cancer campaign tackles confidence failings

Breast Cancer Care aims to address negative impact on how women feel about their bodies

- PMLiVE

UK’s Cancer Drugs Fund given new lease of life

Government invests £400m and pledges Fund will remain until 2016

National Institute for Health and Care Excellence NICE logo

NICE to update ovarian cancer drug guidelines

Draft guidance backs paclitaxel and Janssen’s Caelyx but not gemcitabine, topetecan or trabectedin

- PMLiVE

Mixed news for Lilly on cancer hope ramucirumab

Fails in phase III for breast cancer but better results for stomach cancer

- PMLiVE

Pfizer’s Xalkori ‘not good value for money’, says NICE

Final guidance does not recommend lung cancer drug

Roche - Basel

Roche’s Kadcyla and Bayer’s Xofigo near EU approval

Cancer drugs receive CHMP backing

Roche Basel Switzerland

Roche: Keep Cancer Drugs Fund until VBP shown to work

Company says uncertainty remains about impact of new UK pricing system

- PMLiVE

Pharma firms ramp up Cancer Drugs Fund pressure

Novartis, Roche and Sanofi join forces to highlight public attitudes to medicines access

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links